Response to Comments: Multimarker Serum Tests Related to Ovarian Cancer Testing

This document is a response to public comments regarding the Multimarker Serum Tests LCD for ovarian cancer and does not itself define clinical coverage criteria, limitations, or documentation requirements. The official notice period began May 14, 2020 and the final LCD became effective for services rendered on or after July 1, 2020.

"This document is a response to public comments and does not specify clinical documentation or claim-substantiation requirements for multimarker serum tests related to ovarian cancer."

Sign up to see full coverage criteria, indications, and limitations.